Marshall Wace, LLP Seres Therapeutics, Inc. Transaction History

Marshall Wace, LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$2.7 - $7.62 $920,403 - $2.6 Million	340,890 New	340,890 $1.17 Million
Q1 2022 May 16, 2022	SELL	$6.3 - $8.84 $774,931 - $1.09 Million	-123,005 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$6.02 - $11.43 $655,848 - $1.25 Million	-108,945 Reduced 46.97%	123,005 $1.02 Million
Q3 2021 Nov 15, 2021	BUY	$5.46 - $22.6 $1.27 Million - $5.24 Million	231,950 New	231,950 $1.61 Million
Q4 2019 Feb 14, 2020	SELL	$2.99 - $4.42 $193,880 - $286,606	-64,843 Closed	0 $0

Q3 2019 Nov 14, 2019	SELL	$2.29 - $4.16 $874,452 - $1.59 Million	-381,857 Reduced 85.48%	64,843 $260,000
Q2 2019 Aug 14, 2019	BUY	$2.28 - $7.35 $738,970 - $2.38 Million	324,110 Added 264.39%	446,700 $1.44 Million
Q1 2019 May 14, 2019	BUY	$4.83 - $7.21 $592,109 - $883,873	122,590 New	122,590 $842,000

100

62.7M

36.9K

476K

Ticker MCRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,072,000
Market Cap $89.3M
Description
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.